PROGRAM ISCP 2007

							PROGRAM ISCP 2007


November 30,2007 Friday
                                        Hall I
9.00-10.30
Session 1
Plenary Session
CLINICAL TRIALS IN PERSPECTIVE
Chairs: J.Abrahms (USA)
      A.Bayes deLuna (Spain)

Progress and problems in randomized trials:
From streptomycin to the era of mega trials
E. Antman (USA)

Efficacy and sfety of clinical trials
J.Cohn (USA)

Placebo and nocebo in cardiovascular health:Implications for clinical trials
Ethics and patient-doctor relationship
P.Pool-Wilson (UK) L.Opie (South Africa)

Minorities in clinical trials:Women and the elderly
M.Flather (UK)

10.30 -11.00     Break


11.00-12.30
Session 2
Core Curriculum
Hypertension and heart failure continuum
Chairs:L.Opie (S.Africa), S.Erdine (TR)

From hypertension to heart failure:Epidemiologic facts for the disease
continuum
E.Ambrossioni (I)

From hypertension to heart failure: Pathophysiologic perspectives
W.Louis (USA)
From blood pressure control to prevention and outcome improvement of heart
failure
J.McNeil (Aus) or D.Duprez (USA)


Hypertension and heart failure:Compelling indications for drug therapy
S. Sheik (Pakistan)

12.30-14.00    Lunch


14.00-15.30
Session 3
Plenary Session
Antithrombotic therapy:Where are we now ?
Chairs: Z.Öngen (TR/ E.Antman (USA)

Antiplatelet therapy-where are we now ?
L.Wallentin (Sweden)

Oral anticoagulation-what is new ?
F.Verheught (NL)

Aspirin and clopidogrel resistance:Fact or fancy?
G.Lip (UK) or L.Tokgözoğlu (TR)

New antithrombotic drugs ? The oral Factor Xa inhibitors, oral direct thrombin
inhibitors and beyond.
WF VanGielst (NL)

Long-term antiplatelet strategies for chronic vascular diseases
M.Flather ( UK)




15.30-16.00     Break


16.00-17.30
Session 4
Joint Session ISHNE
Cardiovascular drug safety
Chairs: A. Capucci (I)
       A.John Camm (UK) or A.Oto (TR)

Drug induced torsade des pointes :Mechanisms and scope of the problem
G.Breithardt (Münster,Germany)

Nowel Methods for QT and T wave monitoring in drug testing
W.Zareba (Rochestre-USA)

QRS safety (Na Channel blockers)
N.El Sheriff (USA)

Drugs shorten sinus node
J. Camm

Cardiovascular effects of Cox inhibitors and HDL levating drugs:Viox and
Torcetrabip story
Grazyna Zareba (Rochester-USA)




Hall 2

9.00-1030
Session 5
Basic Science
Genomics:A key strategy in diagnosis,prognosis and management of
cardiovascular diseases
Chairs: I Hakkı Ayhan (TR )
       WF VanGielst (NL)

Clinical pharmacogenomics of beta adrenergic system
B.Pritchard (UK)

Genomics of sudden cardiac death
S. Priori (I)

Variability in response to antiplatelet therapy
L. Wallentin (Sweden)

Pharmacogenomics of heart failure
P.Vanhoutte (China)

Gene and cell based angiogenic therapy
H.P. Schultheiss (Germany)




10.30-11.0   Break


11.012.30
Session 6
Core Curriculum
Pharmacotherapy of atrial fibrillat,on
Chairs: G.A:Dan (Rumania)
        G.Breithardt (Germany)

Historical perspectives
B.Lüderitz (Germany)

Rate control-where are we now ?
A.Capucci (I)

Rhythm control-what is new,what is to come
A.J.Camm (UK)
Antithrombotic therapy and stroke risk stratification
G.Lip (UK)




12.30-14.0   Lunch


14.00-15.30
Session 7
Consensus Workshop
Pharmacotherapy in difficult entities
Chairs: L.Opie (S Africa )
       K. Sethi (India)

Pharmacotherapy for inherited channelopathies
W.Zareba (USA)

Pharmacotherapy in hypertrophic cadiomyopathies
D.Cokkinos (Greece)

Phamachoterapy for sudden cardiac death
S.Priori (I)

Pharmacotherapy for pulmonary hypertension
L.Tokgözoğlu (TR)



15.30-16.00    Break


16.00-17.30
Session 8
DEBATE

Chairs:E.Ambrosioni (I)
      K. Stoschitzky (Austria)

I.ACE inhibition is more effective than AII receptor blockade in cardiovascular
diseases.

Pro. E. Antman (USA)
Con.M. Böhm (Germany)


II.The management of stable angina pectoris is medical not PCI

Pro.P.Pool-Wilson (UK)
Con.P. serruys (NL)

III. The death of EF is overdue
Pro.J. Camm(UK)
Con. J. Cleland (UK)
December 1st,2007 Saturday


Hall I

9.00-10.30
Session 9

Plenary Session
Pharmacotherapy of hypertension: Beyond mega trials
Chairs:K.Stoschitzky (Austria)
      J.McNeil (Australia)


Clinical trials and guidelines in hypertension-old drugs and new ones to come
L.Opie (S Africa)

Should pharmacogenetics influence our decision to treat ?
W.J.Louis (USA)

Future of beta blockers:Shoul we give them up in antihypertensive therapy ?
B.N.C. Pritchard (UK)

What is the role of antiplatelet therapy and statins ?
R.Paoletti (I)

Beyon BP control
J. Cohn (USA)


10.30-11.0 Break


11.00-12.30
Session 10

Joint Session of EAS-ISCP
Treating dislipidemia in 2007
Chair:Marja-Riitta Taskinen (Helsinki,Fin)
      W.J.Louis

Will raising HDL prevent atherosclerosis ? :New phramachologic options
Lale Tokgözoğlu ( Ankara-Turkey)


Treating hypertriglyceridemia after FIELD
Marja-Riitta Taskinen (Helsinki,Finland )

What is new in LDL lowering ?
Vedat Sansoy (İstanbul-Turkey )

Is inflammation a clinically relevant target for treatment of atherosclerosis?
Gerd Hannson (Stockholm-Sweden) or Gerhard Wick (Innsburck –Austria)


12.30-14.0 Lunch


14.00-15.30
Session 11
Plenary Session
ACS: Paradigms and new perspectives in pharmacotherapy
Chairs:S.Sheik (Pakistan )
      J.Abrahms (USA)

A synopsis of landmark trials and how they should direct the conemporary
strategies
For patients with non ST elevation ACS (Risk evaluation/early invasive vs
conservative startegies etc)
J.C.Kaski (UK)

State of the Art antithrombotic therapy 2007-04-
24(LMWH,Fondaparinux,Bivalirudin etc)
F. Verheught (NL)

Fibrinolysis : Optimal use in STEMI
F. Van de Werf (Belgium ) or E Antman (USA)


Triple antiplatelet therapy:When do we need it ?
   A. Battler (Israel)

Discharge therapy
N. Danchin (France)
15.30-16.0    Break




16.00-17.30
Session 12
Core curriculum
New insights in the treatment of heart failure
Chairs: M. Böhm (Germany)
        R. Oganow (Russia)

Do new drugs really work in heart failure ?
J. Cleland (UK)

Stem cell hope /hype in 2007
HP Schultheiss (Germany)

Emerging therapies for the management of decompansated heart failure
J. Tamargo (Spain)

Racial or ethnic response differences in heart failure
J. Cohn (USA)

Treatment of right heart failure
K. Aytemir (TR)
Hall II

9.00-10.30
Session 13
Consensus Workshop
Upstream therapy for atrial fibrillation
Chairs: B.Özin (TR)
       G.Lip (UK)


Statins
C.Jazzra (Lebanon )


ARB’s
A. Maggioni (I)

Fishoil
F. Nacarella (I)

Antinflammatory drugs
G. A. Dan (Rumania ) or
F.Follath (Switzerland)




Break



11.00-12.30
Session 14
Symposium
New paradigms in RAAS inhibition strategies
Chairs: A: Maggioni (I)
        F. Follath (Switzerland)

An ARB, an ACE-i or an ARB+ACE-i?
M. Böhm (Germany)

RAAS blockade.Towards the optimization by renin inhibitors
J.W.Louis
Pleitropic effects of ARB’s:What have we learned from clinical trials ?
F.Martinez (Argentina )

RAAS as a therapeutic target in diabetes
K. Stoschitzky (Austria)


Lunch

14.00-15.30
Session 15
Core Curriculum
New targets in cardiovascular pharmacotehrapy
Chairs:I H. Ayhan (TR)
      P.Clemmensen (Denmark)

Slowing the heart rate
J. Camm (UK)

Endocannabioid receptors
P. Deedwania (USA)

HDL raising
D.Duprez (USA)

PPAR Gamma
H. Orer (TR)

Break


16.00-17.30
Session 16
Symposium
Hot issues in cardiocvascular pharmacotherapy: Diabetes and cardiovascular
system
Chairs:P. Deedwania (USA)
       A.Pakramenko (Ukraine)

Do new antidiabetics improve long-term survival?
M.Bayraktar (TR)
Treatment of diabetic dislipidemia
D.Duprez (USA)

How to approach diabetic hypertensives
E. Ambrossioni (I)

Post prandial hyperglycemia and ACS
J.C.Kaski (UK)

Insulin therapy in CCU
S. Akalın (TR)




Dec2 nd,2007 Sunday

Hall I

9.00-10.30
Session 17
Consensus Workshop
Management of cardiovascular diseases in the elderly
Chairs:M. Kenda (Slovenia)
      A.Bayes deLuna (Spain)


Lipid management in the elderly:Is it eve toolate ?
R Paoletti (I)
Management of hypertension in the elderly:Does age matter ?
F. Follath (Switzerland)
Or J.McNeil (Austraila)

Heart failure management inhe elderly:What are the differences
J. Cleland (Uk)
Or J.R.Gonzalez (Spain)

Treatment of AF:How aggressive should be ?
B. Lüderitz (Germany ) or G.Lip (UK)




10.30-11.0 Break



11.00-12.30
Session 18
Plenary Session
Clinical trials update

Chairs:M. Böhm (Germany )
      J. Cohn (USA)

Clinical trials in AF
A.J. Camm (UK)

Clinical trials in HF
J. Cleland (UK)


Clinical trials in HT
,A. Maggioni (I)

Clinical trials in lipid disorders and atherosclerosis
M.R.Taskinen (Finland)
Clinical trials in ischemic heart diseases
J. Abrahms (USA)




12.30- Lunch




Hall II

9.00-10.30
DEBATE


I.In persons optimally treated with diuretics, ACE-inhibitors and beta
blockers,aldosterone inhibitors are the next treatment not ARB’s.

Pro.P.P.Wilson (UK)
Con.J.Cleland

II.Antiplatelet therapy should be added to anticoagulant therapy in patients with
AF and vascular disease ?
Pro.G.Lip (UK)
Con.F. Verheught (NL)


III.A standart high dose statin is to be used in all patients at risk

Pro.F. Cruz(Spain) or V Sansoy (TR)
Con.D.Duprez (USA)


10.30-11.00     Break


11.00-12.30

Core curriculum
Obesity
Chairs:Dayi Hu (China)
      N.Gothceva (Bulgaria)

Treating the obesity to reduce cardiovascular risk
F.Cruz (Spain)

Drug therapy for weight loss
J.R. Gonzales Juanatey (Spain)

From metabolic sendrom to cardiometabolic risk
P. Deedwania (USA)

Adinopectin and risk of ACS:Defining the obesity phenotype
P.Clemmenson (Denmark)

Leptin and vascular function:A friend or foe ?
Dayi Hu (China)